Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 6/20 | 0.60 |
| ▸ | ACHE | P22303 | 1/20 | 0.51 |
| ▸ | PARP10 | Q53GL7 | 14/20 | 0.47 |
| ▸ | PARP11 | Q9NR21 | 13/20 | 0.47 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.41 |
| ▸ | GRM5 | P41594 | 1/20 | 0.40 |
| ▸ | PARP15 | Q460N3 | 1/20 | 0.40 |
| ▸ | PARP14 | Q460N5 | 1/20 | 0.40 |
| ▸ | TIPARP | Q7Z3E1 | 1/20 | 0.40 |
| ▸ | PARP16 | Q8N5Y8 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4638131 | 0.90 | PARP1 (0.49) | PARP1ACHEPARP10PARP11PDPK1 | |
| SCHEMBL4165821 | 0.82 | ACHE (0.54) | PARP1ACHEPARP10PARP11PDPK1 | |
| SCHEMBL8260242 | 0.79 | PARP1 (0.60) | PARP1ACHEPARP10PARP11PDPK1 | |
| SCHEMBL14992245 | 0.79 | ACHE (0.51) | PARP1ACHEPARP10PARP11PDPK1 | |
| SCHEMBL29914781 | 0.79 | PARP10 (0.60) | PARP1ACHEPARP10PARP11PDPK1 | |
| SCHEMBL7581623 | 0.75 | PARP1 (1.00) | PARP1ACHEPARP10PARP11PDPK1 | |
| SCHEMBL15299930 | 0.74 | CASP1 (0.41) | PARP1 | |
| SCHEMBL29007917 | 0.74 | NOTUM (0.46) | PARP1ACHE | |
| SCHEMBL6421827 | 0.71 | PARP1 (0.64) | PARP1ACHEPARP10PARP11PDPK1 | |
| SCHEMBL29587371 | 0.71 | PARP1 (0.64) | PARP1ACHEPARP10PARP11PDPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090099231-A1 | 3-Sulfonylamino-Pyrrolidine-2-One Derivatives as Factor Xa Inhibitors | GLAXO GROUP LIMITED (GB) | 2009-04-16 | — | — | US | disclosed |
| US-20090099231-A1 | 3-Sulfonylamino-Pyrrolidine-2-One Derivatives as Factor Xa Inhibitors | GLAXO GROUP LIMITED (GB) | 2009-04-16 | — | — | US | disclosed |
| US-20090099231-A1 | 3-Sulfonylamino-Pyrrolidine-2-One Derivatives as Factor Xa Inhibitors | GLAXO GROUP LIMITED (GB) | 2009-04-16 | — | — | US | disclosed |
| EP-1869010-A1 | 3-SULFONYLAMINO-PYRROLIDINE-2-ONE DERIVATIVES AS FACTOR XA INHIBITORS | GLAXO GROUP LIMITED (GB) | 2007-12-26 | — | — | EP | disclosed |
| WO-2006108709-A1 | 3-SULFONYLAMINO-PYRROLIDINE-2-ONE DERIVATIVES AS FACTOR XA INHIBITORS | GLAXO GROUP LIMITED (GB) | 2006-10-19 | — | — | WO | disclosed |
| WO-2006108709-A1 | 3-SULFONYLAMINO-PYRROLIDINE-2-ONE DERIVATIVES AS FACTOR XA INHIBITORS | GLAXO GROUP LIMITED (GB) | 2006-10-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090099231-A1 | 3-Sulfonylamino-Pyrrolidine-2-One Derivatives as Factor Xa Inhibitors | TFPI, SERPINC1, SERPINE1 | PARP1 205/4885ACHE 2043/4885PARP10 447/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.